Completed PHASE4 INTERVENTIONAL 1-arm NCT03310073

Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV

Immunogenicity and Safety Profile of Primary Dose of Bivalent OPV (bOPV Bio Farma) Given Simultaneously With Pentabio® And Inactivated Poliovirus Vaccine (IPV) at the 4th Visit in Indonesian Infants

Sponsor: PT Bio Farma

Conditions Healthy

Interventions IPV Pentabio bOPV

Updated 5 times since 2017 Last updated: Nov 6, 2017 Started: Jul 31, 2016 Primary completion: Mar 31, 2017 Completion: Mar 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03310073, this PHASE4 trial focuses on Healthy and remains completed. Sponsored by PT Bio Farma, it has been updated 5 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Oct 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PT Bio Farma

Data source: PT Bio Farma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bandung, Indonesia